<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>识林 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-05T07:23:03+08:00</updated>
  <subtitle>服务于制药行业企业、机构及人员的知识与管理平台</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>如何执行 OOS 根本原因调查：假设检验</title>
    <updated>2020-12-05T06:57:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/llC9Mio2qvsXUzRvRbp7qQ</id>
    <link href="https://mp.weixin.qq.com/s/llC9Mio2qvsXUzRvRbp7qQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 指南草案阐明如何执行与抑酸剂的药物相互作用研究</title>
    <updated>2020-12-04T06:33:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/92zodQ2i_aYMXI7DPLqd1w</id>
    <link href="https://mp.weixin.qq.com/s/92zodQ2i_aYMXI7DPLqd1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞和 Moderna 面临压力和批评，未承诺向发展中国家提供新冠疫苗</title>
    <updated>2020-12-04T06:33:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/DWWYuYnw7-_KZ6IxewwGcw</id>
    <link href="https://mp.weixin.qq.com/s/DWWYuYnw7-_KZ6IxewwGcw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>英国率先授权辉瑞新冠疫苗，欧盟和美国怎么看？</title>
    <updated>2020-12-03T06:30:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/OfazhT2uyuP9VOrss4-u9A</id>
    <link href="https://mp.weixin.qq.com/s/OfazhT2uyuP9VOrss4-u9A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中英对照：WHO 生物等效性研究方案中的常见缺陷（下）</title>
    <updated>2020-12-03T06:30:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/TIZFXM-VCCaEatTrMTVxzw</id>
    <link href="https://mp.weixin.qq.com/s/TIZFXM-VCCaEatTrMTVxzw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中英对照：WHO 生物等效性研究方案中的常见缺陷（上）</title>
    <updated>2020-12-02T06:32:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/qJQNjHTEilYucUo940RmJA</id>
    <link href="https://mp.weixin.qq.com/s/qJQNjHTEilYucUo940RmJA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>IPEM课程：欧盟无菌附录、无菌GMP风险管理和检查及WHO疫苗PQ认证</title>
    <updated>2020-12-02T06:32:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/CNl91ET_v8mDVVIJ6R7Ulg</id>
    <link href="https://mp.weixin.qq.com/s/CNl91ET_v8mDVVIJ6R7Ulg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 全球质量基准研究初步分析结果</title>
    <updated>2020-12-01T06:36:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/c3wLS3ah3g7bOfSF5M4B8g</id>
    <link href="https://mp.weixin.qq.com/s/c3wLS3ah3g7bOfSF5M4B8g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 启动新药创新科学和技术方法（ISTAND）试点计划</title>
    <updated>2020-12-01T06:36:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/7cazWZl5I_9UrNtyAeG_oA</id>
    <link href="https://mp.weixin.qq.com/s/7cazWZl5I_9UrNtyAeG_oA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一周回顾：新专利法颁布，专利法实施细则修订，欧洲药物战略，FDA 2020 财年检查观察项列表，复杂仿制药会议指南</title>
    <updated>2020-11-30T05:28:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/ukq1riJZgUVDEO45eVhGRw</id>
    <link href="https://mp.weixin.qq.com/s/ukq1riJZgUVDEO45eVhGRw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康新冠疫苗申请放弃高保护效力数据，英国开始滚动审评美国可能不会接受</title>
    <updated>2020-11-30T05:28:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/ZAG6v00Ywm4qQwbJrO1IMA</id>
    <link href="https://mp.weixin.qq.com/s/ZAG6v00Ywm4qQwbJrO1IMA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【周末杂谈】受益与贡献</title>
    <updated>2020-11-29T06:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/Jv9quihn6LsxGBpgU2zPWg</id>
    <link href="https://mp.weixin.qq.com/s/Jv9quihn6LsxGBpgU2zPWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 2020 财年药品检查观察项和趋势</title>
    <updated>2020-11-28T06:38:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-28:/s/MkinQNYfk7DB4tKsqExtKw</id>
    <link href="https://mp.weixin.qq.com/s/MkinQNYfk7DB4tKsqExtKw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>欧盟发布药物战略强调仿制药竞争和强制许可等问题</title>
    <updated>2020-11-27T05:29:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/EayiDHO1d6WPFGWDBdCx3g</id>
    <link href="https://mp.weixin.qq.com/s/EayiDHO1d6WPFGWDBdCx3g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 解释瑞德西韦批准依据，暗驳 WHO 的否定建议</title>
    <updated>2020-11-27T05:29:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/PR9czbGF-_M7BVU0OKDmDw</id>
    <link href="https://mp.weixin.qq.com/s/PR9czbGF-_M7BVU0OKDmDw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 远程记录审查缺乏沟通互动引发业界担忧</title>
    <updated>2020-11-26T06:00:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/qmGeOrPpyiNg1zboj9UuIQ</id>
    <link href="https://mp.weixin.qq.com/s/qmGeOrPpyiNg1zboj9UuIQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA 发布复杂仿制药开发和申报正式会议定稿指南</title>
    <updated>2020-11-26T06:00:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/qmcwSMnUy5W2G_PW4VS9fA</id>
    <link href="https://mp.weixin.qq.com/s/qmcwSMnUy5W2G_PW4VS9fA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>